As per file attached.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies reported strong FY2026 results with standalone revenue from operations of Rs 768.73 crore, up 19.3% from Rs 644.47 crore in FY2025. Net profit surged 89% to Rs 99.31 crore from Rs 52.55 crore, while consolidated net profit jumped 127% to Rs 102.78 crore. EBITDA expanded significantly to Rs 155.37 crore from Rs 90.77 crore. The Board declared a 100% dividend (Rs 10 per share) subject to shareholder approval at the 37th AGM on August 20, 2026. Key appointments include Dr. Savita Gupta as Additional Director (related party to Managing Director Mr. Pawan Chaudhary), and reappointment of Mr. Saransh Chaudhary and Dr. Gurminder Singh Bedi as Independent Directors. New cost and internal auditors were appointed for FY2026-27. The company adopted new MOA and AOA aligned with Companies Act 2013. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated results.
Strong operational performance with near 90% PAT growth signals robust business health. The 100% dividend payout is positive for shareholders. Related party appointment of Dr. Savita Gupta requires disclosure. Clean audit opinion with no going concern issues indicates financial stability.